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ABSTRACT 
 
Genetic Analyses of the in Vivo Functions of the Oncoprotein CDK8 in Drosophila. (May 
2012) 
 
 
Lauren M Bridges and Gee Yoon Park 
Department of Molecular and cellular Biology  
Texas A&M University 
 
Research Advisor: Dr. Jun-yuan Ji 
Department of Molecular and Cellular Biology 
 
Cyclin-Dependent Kinase 8 (CDK8) has recently emerged as an oncoprotein that is 
amplified in  both colorectal and melanoma cancers. The importance of CDK8 and its 
regulatory partner Cyclin C (CycC) is highlighted by the clinical observations showing 
that CDK8 and CycC are frequently amplified, mutated, or deleted in a variety of 
human cancers4. Inhibiting CDK8 potently blocks the growth of colorectal cancer cells 
that harbor CDK8 amplification, suggesting that CDK8 is a promising drug target. 
Accordingly, several pharmaceutical companies are tremendously interested in 
developing CDK8-specific inhibitors5. However, for such drugs to be  successful, it is 
essential to understand the regulatory network of CDK8-CycC including both the upstream 
regulators and the downstream  effectors in normal development and tumorigenesis. To 
date, little is known about how CDK8-CycC activity is regulated. In addition, the 
downstream targets and the biological functions of CDK8 in metazoans remain poorly 
understood.  
iv 
 
Importantly, both CDK8 and CycC are highly conserved in all eukaryotes. Thus 
we use Drosophila as an experimental system to identify both the upstream regulators and 
downstream effectors of CDK8. We expect to elucidate the fundamental roles of CDK8- 
CycC and thereby gain insight of how their deregulations contribute to various cancers.  
Because cdk8 or cycC homozygous mutants are lethal in the pupal stage, we set out 
to vary CDK8 and CycC in a tissue-specific manner by using the Gal4-UAS system.  
Importantly, certain phenotypes can be modified by second-site mutations, which 
provide us with a unique opportunity to genetically dissect the functions and regulation of 
CDK8-CycC in vivo.  
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NOMENCLATURE 
 
 
 
CDK8 Cyclin-dependent kinase 8 
 
CycC Cyclin C 
UAS Upstream activating sequence 
RNAi RNA interference 
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CHAPTER I 
 
INTRODUCTION 
 
Cyclin-Dependent Kinase 8 (CDK8) is a newly identified oncoprotein that is amplified in 
both colorectal and melanoma cancers (1-3). The importance of CDK8 and its 
regulatory partner Cyclin C (CycC) is highlighted by the clinical observations showing 
that CDK8 and CycC are frequently amplified, mutated, or deleted in a variety of human 
cancers (4). Inhibiting CDK8 potently blocks the growth of colorectal cancer cells that 
harbor CDK8 amplification, suggesting that CDK8 is a promising drug target. 
Accordingly, several pharmaceutical companies are developing and testing CDK8-
specific inhibitors (5). However, for such drugs to be successful, it is essential to 
understand the regulatory network of CDK8-CycC including the upstream regulators 
and the downstream effectors in both normal development and tumorigenesis. To date, little 
is known about how CDK8-CycC activity is regulated. In addition, the downstream targets  
and the biological functions of CDK8 in metazoans remain poorly understood.  
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Figure 1 Varying CDK8 in fly wings generates stable and modifiable phenotypes.  (A) wild-type wing;  
(B) over-expression of CDK8 in the wing; and (C) knocking down CDK8. 
Drosophila is a well-established model system because it provides a variety of sophisticated 
and powerful genetic approaches. Compared to mammals, it is much simpler, yet many 
regulatory mechanisms are conserved at the molecular level. Importantly, both CDK8 and 
CycC are highly conserved in all eukaryotes. Thus we use Drosophila as an experimental 
system to identify both the upstream regulators and downstream effectors of CDK8. 
We expect to elucidate the fundamental roles of CDK8-CycC and thereby gain insight of 
how their deregulations contribute to various cancers.  
 
Because cdk8 or cycC homozygous mutants are lethal in the pupal stage (6), we set out to 
vary CDK8 and CycC in a tissue-specific manner. For this, we applied the well-established 
Gal4-UAS system, which allows us to express the wild-type (or dsRNA) of 
cdk8/cycC, thereby over-expressing (or knocking down) CDK8/CycC in a tissue-
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specific manner. As shown in Fig. 1, when driven by using a wing-specific Gal4 line 
nubbin-Gal4, the overexpression of cdk8 severely disrupts the vein patterns (Fig. 1B, 
compared to the control in Fig. 1A). Conversely, knocking down cdk8 leads to an 
opposite phenotype with ectopic veins in the inter-vein regions (Fig. 1C). Similar 
phenotypes were observed when we varied CycC levels (data not shown). Such 
phenotypes are highly stable with nearly 100% penetrance. Importantly, these phenotypes  
can be modified by second-site mutations (see below), which provide us with a 
unique opportunity to genetically dissect the functions and regulation of CDK8- CycC in 
vivo.  
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CHAPTER II  
 
METHODS 
 
Drosophila was used as an experimental system.  We applied the well-established 
Gal4-UAS system  which  allowed  us  to  express  the  wild  type (or  dsRNA)  of  
cdk8/cycC,  thereby overexpressing CDK8/CycC in a tissue-specific manner.  The 
initial screen was based on phenotypes caused by over-expression  or  knockdown  of  
CDK8.  We utilized the new Bloomington Deficiency kit, which provides maximal 
coverage of the genome (~98% of Drosophila euchromatic    genome)    with    the    
minimal    number    of    deletions (http://flystocks.bio.indiana.edu/Browse/df/dfkit-
info.htm).   This   deficiency   collection   is composed  of 468  deletions  and  
breakpoints  that  are  molecularly  mapped  to  single-base resolution for most of the 
deletions. This approach allowed us to efficiently survey through the Drosophila genome 
for factors that interact with CDK8 by crossing less than 500 crosses and still be able to 
go through 97.9% of the drosophila genes. 
 
Specifically, we crossed each deficiency line with nub-Gal4, UAS-CDK8 (wild type or 
RNAi), and then scored the lines that can modify the phenotypes caused by varying 
CDK8. Figure 2 outlines the scheme for the genetic crosses (using a second 
chromosome deficiency line as an example) and shows each example of an enhancer and 
a suppressor. We finished the first round of the screen using the CDK8-RNAi phenotypes 
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and identified 53 enhancers (16 of them are strong enhancers) and 37 suppressors (6 of 
them are strong suppressors).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Phenotypes for CDK8 enhancers and suppressors. 
We retested these modifier deficiency lines with the wing phenotypes caused by CDK8 
overexpression and knocking down of CycC.  To narrow down to specific mutant genes, 
we tested partially overlapping deficiency lines with the dominant modifier deficiency 
lines. Once we narrowed down to regions with less than ten genes, we tested all the 
mutants available for those genes and then performed genetic crosses to identify the 
candidate gene that is responsible for uncovering the deletion line.  
Figure 2 exhibits a stereotypical result of a cross with an enhancer and a suppressor.  In 
Figure 1A, we can observe the stereotypical wild-type Drosophila wing vein pattern.  
When we specifically over-express Cdk8 in the wing, we see loss of vein patterns, as 
exhibited in Figure 1B. On the other hand, when we deplete Cdk8 in the wing, we 
observe ectopic, or extra, veins that formed as illustrated in Figure 1C.  These 
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phenotypes are 100% penetrant, allowing us to build stable stocks and screen for 
mutants that can modify these phenotypes.  If a mutant worsens these phenotypes, we 
call it an enhancer, while if a mutant makes the phenotypes stronger, we call it a 
suppressor.  This kind of genetic analyses allowed us to identify novel factors that 
regulate Cdk8 in vivo.  
Because Cdk8/CycC mutants are lethal in the pupal stage, it was necessary for us to devise 
a new method of manipulating Cdk8 activities in Drosophila.  We utilized the so-
called Gal4-UAS system.  Gal4 is a yeast transcription factor that specifically binds 
to the upstream activating sequence (UAS).  On one hand, we were able to generate 
transgenic flies to overexpress wildtype Cdk8 using Gal4 lines that are expressed in 
tissue-specific manners, thereby resulting in gain of Cdk8 phenotypes in certain 
tissues.  Alternately, we can reduce or deplete Cdk8 by expressing double-stranded 
RNA through a process known as RNA interference (RNAi), thereby resulting in a loss of 
Cdk8 phenotypes in certain tissues.  
We plan to expand this same approach to the rest of the strong modifiers that we have 
identified. We expect to identify multiple novel factors that genetically interact with 
CDK8.  We will select modifiers that are involved in transcription regulation and 
signal transduction for further characterization.  
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CHAPTER III  
RESULTS 
 
We crossed each deficiency line with nub-Gal4, UAS-CDK8 (wild-type or RNAi), and 
CycC. We then scored the lines that can modify phenotypes caused by varying CDK8.  
Our first round of the genetic screen identified fifty-three enhancers and thirty-seven 
suppressors.  Sixteen of the enhancers were strong enhancers and six of the suppressors 
were strong suppressors.  After retesting these modifier deficiency lines, we determined 
the regions that contained less than ten genes.  We had four overlapping enhancers and 
one overlapping suppressor between Cdk8-RNAi and CycC-RNAi as can be seen in 
Figure 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 First and second cross results depicting modifiers identified 
as either enhancing or suppressing Cdk8 expression. 
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CHAPTER IV 
 
SUMMARY AND CONCLUSIONS 
 
To summarize, we started out with nearly 500 crosses of the entire Drosophila 
genome and narrowed down to approximately 70 different modifiers after the first round 
of screening by the help of other researchers in the lab. 44 modifiers for both cdk-8 and 
cycC enhancers and 28 for suppressors were identified on the first round of crosses. We 
are currently working our ways down to narrowing we were able to design a genetic 
screen that enabled us to identify four overlapping enhancers and one overlapping 
suppressor, thus far on the second round of crosses using a new set of partial deletion 
lines.  We expect to finish the second round within the next month. Once we have 
identified the modifiers for both Cdk-8 and CycC, we expect to find the specific genes in 
each of the suppressors and enhancers that feed the phenotype accordingly. Though the 
function of Cdk8 is currently unknown, by narrowing down to a specific gene region we 
can determine its function.  
 
In conclusion, it is important to discern the molecular development of Cdk8/CycC in the 
future. In the long run, this research will open up many new directions to understand the 
function and regulation of Cdk8/CycC in vivo.  A better understanding of the function of 
Cdk8 will provide us with the knowledge to develop anti-cancer drugs that can target the 
specific gene region that is involved in tumorigenesis. 
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